Mastocytosis
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Mastocytosis Classification and external resources | |
 | |
|---|---|
| Skin: Cutaneous Mastocytosis; childhood form (A), there is a tumoral dermal infiltrate devoid of epidermotropism and composed of bland cells with conspicuous cell boundaries and uniform, round, centrally located nuclei (B). Confirmatory cytoplasmic granules are only apparent with metachromatic stains, such as this Giemsa stain (C), or by upon ultrastructural examination (D). C, X1000. D, X65,000. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology | |
| ICD-10 | Q82.2, C96.2 |
| ICD-9 | 757.33, 202.6 |
| ICD-O: | 9741/3 |
| OMIM | 154800 |
| DiseasesDB | 7864 |
| eMedicine | derm/258 med/1401 |
| MeSH | D008415 |
|
WikiDoc Resources for Mastocytosis | |
|
Articles | |
|---|---|
|
Most recent articles on Mastocytosis Most cited articles on Mastocytosis | |
|
Media | |
|
Powerpoint slides on Mastocytosis | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Mastocytosis at Clinical Trials.gov Clinical Trials on Mastocytosis at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Mastocytosis
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Mastocytosis Discussion groups on Mastocytosis Patient Handouts on Mastocytosis Directions to Hospitals Treating Mastocytosis Risk calculators and risk factors for Mastocytosis
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Mastocytosis | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Mastocytosis is a group of rare disorders of both children and adults caused by the presence of too many mast cells (mastocytes) and CD34+ mast cell precursors in a person's body.[1] [1] [1] [1]
Epidemiology
No one is sure how many people have either type of mastocytosis, but mastocytosis generally has been considered to be an "orphan disease" (orphan diseases affect 200,000 or fewer people in the United States). Mastocytosis, however, often may be misdiagnosed, and occur more frequently than assumed.
Pathophysiology
Mast cells are located in connective tissue, including the skin, the linings of the stomach and intestine, and other sites. They play an important role in helping defend these tissues from disease. By releasing chemical "alarms" such as histamine, mast cells attract other key players of the immune defense system to areas of the body where they are needed.
Mast cells seem to have other roles as well. Because they gather together around wounds, mast cells may play a part in wound healing. For example, the typical itching felt around a healing scab may be caused by histamine released by mast cells. Researchers also think mast cells may have a role in the growth of blood vessels (angiogenesis). No one with too few or no mast cells has been found, which indicates to some scientists that we may not be able to survive with too few mast cells.
Mast cells express a cell surface receptor termed c-kit[1] (CD117), which is the receptor for scf (stem cell factor). In laboratory studies, scf appears to be important for the proliferation of mast cells, and inhibiting the tyrosine kinase receptor with imatinib (see below) may reduce the symptoms of mastocytosis.
History
Scientists first described urticaria pigmentosa in 1869.[1] Systemic mastocytosis was first reported by scientists in 1936.[1]
Classification
The presence of too many mast cells, or mastocytosis, can occur in a variety of forms.
- Most cases are cutaneous (confined to the skin only). There are several forms of cutaneous mastocytosis. The most common is called urticaria pigmentosa (UP). It mostly affects children. Telangiectasia Macularis Eruptiva Perstans (TMEP) is a much rarer form of cutaneous mastocytosis that affects adults.[1]
- Systemic mastocytosis involves the internal organs, usually in addition to involving the skin. Mast cells collect in various tissues and can affect organs such as the liver, spleen, lymph nodes, and bone marrow.
Symptoms
In some rare cases chemicals released by mast cells cause changes in the immune system leading to typical allergy symptoms such as:
- Itching
- Abdominal cramping
- Anaphylaxis (shock from allergic or immune causes)
When too many mast cells exist in a person's body, the additional chemicals can cause:
- Skin lesions
- Abdominal discomfort
- Episodes of very low blood pressure (including shock) and faintness
- Bone or muscle pain
- Nausea and vomiting
Diagnosis
Can be diagnose urticaria pigmentosa (cutaneous mastocytosis, see below) by seeing the characteristic lesions that are dark-brown and fixed. A small skin sample (biopsy) may help confirm the diagnosis.
By taking a biopsy from a different organ, such as the bone marrow, the doctor can diagnose systemic mastocytosis. Using special techniques on a bone marrow sample, the doctor looks for an increase in mast cells. Another sign of this disorder is high levels of certain mast-cell chemicals and proteins in a person's blood and sometimes in the urine.
Treatment
There is currently no cure for mastocytosis. However, there are a number of medicines to help treat the symptoms of mastocytosis:
- Antihistamines block receptors targeted by histamine released from mast cells. Both H1 and H2 blockers may be helpful.
- Leukotriene antagonists block receptors targeted by leukotrienes released from mast cells.
- Mast cell stabilizers help prevent mast cells from releasing their chemical contents. Cromolyn Sodium Oral Solution (Gastrocrom® / Cromoglicate) is the only medicine specifically approved by the U.S. FDA for the treatment of mastocytosis. Ketotifen is available in Canada and Europe, but is only available in the U.S. as ophthamic drops (Zaditor®).
- Proton pump inhibitors help reduce production of gastric acid, which is often increased in patients with mastocytosis. Excess gastric acid can harm the stomach, esophagus, and small intestine.
- Epinephrine constricts blood vessels and opens airways to maintain adequate circulation and ventilation when excessive mast cell degranulation has caused anaphylaxis.
- Albuterol and other beta-2 agonists open airways that can constrict in the presence of histamine.
- Corticosteroids can be used topically, inhaled, or systemically to reduce inflammation associated with mastocytosis.
- Antidepressants are an important and often overlooked tool in the treatment of mastocytosis. The stress and physical discomfort of any chronic disease may increase the likelihood of a patient developing depression. Depression and other neurological symptoms have been noted in mastocytosis.[1] Some antidepressants such as doxepin are themselves potent antihistamines and can help relieve physical as well as cognitive symptoms.
- Dihydropyridines are calcium channel blockers that are sometimes used to treat high blood pressure. At least one clinical study suggested that Nifedipine, one of the dihydropyridines, may reduce mast cell degranulation in patients that exhibit urticaria pigmentosa. A 1984 study by Fairly et al. included a patient with symptomatic urticaria pigmentosa who responded to nifedipine at dose of 10 mg po tid.[1] However, Nifetipine has never been approved by the FDA for treatment of mastocytosis.
In rare cases in which mastocytosis is cancerous or associated with a blood disorder, the patient may have to use steroids and/or chemotherapy. The novel agent imatinib (Glivec® or Gleevec®) has been found to be effective in certain types of mastocytosis.[1]
There are clinical trials currently underway testing stem cell transplants as a form of treatment.
There are support groups for persons suffering from mastocytosis. Involvement can be emotionally therapeutic for some patients.
Research
National Institute of Allergy and Infectious Diseases (NIAID) scientists have been studying and treating patients with mastocytosis for several years at the National Institutes of Health (NIH) Clinical Center.
Some of the most important research advances for this rare disorder include improved diagnosis of mast cell disease and identification of growth factors and genetic mechanisms responsible for increased mast cell production. Researchers are currently evaluating approaches to improve ways to treat mastocytosis.
Scientists also are focusing on identifying disease-associated mutations (changes in genes). NIH scientists have identified some mutations, which may help researchers understand the causes of mastocytosis, improve diagnosis, and develop better treatments.
References
Additional Resources
- Based on an informative page by the National Institute of Allergy and Infectious Diseases (NIAID).
External links
Acknowledgements
The content on this page was first contributed by: C. Michael Gibson, M.S., M.D.
List of contributors:
Suggested Reading and Key General References
Suggested Links and Web Resources
For Patients
WikiDoc Research Resources for Mastocytosis (Click show to right to view) | |
|---|---|
| Articles on Mastocytosis | Most recent articles on Mastocytosis • Most cited articles on Mastocytosis • Review articles on Mastocytosis • Articles on Mastocytosis in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Mastocytosis | Powerpoint slides on Mastocytosis • Images of Mastocytosis • Photos of Mastocytosis • Podcasts & MP3s on Mastocytosis • Videos on Mastocytosis |
| Evidence Based Medicine Regarding Mastocytosis | Cochrane Collaboration on Mastocytosis • Bandolier on Mastocytosis • TRIP on Mastocytosis |
| Cost Effectiveness of Mastocytosis | Cost Effectiveness of Mastocytosis |
| Clinical Trials Involving Mastocytosis | Ongoing Trials on Mastocytosis at Clinical Trials.gov • Trial results on Mastocytosis • Clinical Trials on Mastocytosis at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Mastocytosis | US National Guidelines Clearinghouse on Mastocytosis • NICE Guidance on Mastocytosis • NHS PRODIGY Guidance • FDA on Mastocytosis • CDC on Mastocytosis |
| Textbook Information on Mastocytosis | Books and Textbook Information on Mastocytosis |
| Pharmacology Resources on Mastocytosis | Dosing of Mastocytosis • Drug interactions with Mastocytosis • Side effects of Mastocytosis • Allergic reactions to Mastocytosis • Overdose information on Mastocytosis • Carcinogenicity information on Mastocytosis • Mastocytosis in pregnancy • Pharmacokinetics of Mastocytosis • |
| Genetics, Pharmacogenomics, and Proteinomics of Mastocytosis | Genetics of Mastocytosis • Pharmacogenomics of Mastocytosis • Proteomics of Mastocytosis |
| Newstories on Mastocytosis | Mastocytosis in the news • Be alerted to news on Mastocytosis • News trends on Mastocytosis |
| Commentary on Mastocytosis | Blogs on Mastocytosis |
| Patient Resources on Mastocytosis | Patient resources on Mastocytosis • Discussion groups on Mastocytosis • Patient Handouts on Mastocytosis • Directions to Hospitals Treating Mastocytosis • Risk calculators and risk factors for Mastocytosis |
| Healthcare Provider Resources on Mastocytosis | Symptoms of Mastocytosis • Causes & Risk Factors for Mastocytosis • Diagnostic studies for Mastocytosis • Treatment of Mastocytosis |
| Continuing Medical Education (CME) Programs on Mastocytosis | CME Programs on Mastocytosis |
| International Resources on Mastocytosis | Mastocytosis en Espanol • Mastocytosis en Francais |
| Business Resources on Mastocytosis | Mastocytosis in the Marketplace • Patents on Mastocytosis |
| Informatics Resources on Mastocytosis | List of terms related to Mastocytosis |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
